Impact	O
of	O
Blood	B:C0005841
Transfusions	I:C0005841
on	O
Survival	O
of	O
Locally	O
Advanced	O
Cervical	O
Cancer	I:C4048328
Patients	O
Undergoing	O
Neoadjuvant	O
Chemotherapy	O
Plus	O
Radical	O
Surgery	I:C0543467
.	O

Impact	O
of	O
Blood	O
Transfusions	I:C0005841
on	O
Survival	O
of	O
Locally	B:C1517927
Advanced	O
Cervical	O
Cancer	I:C4048328
Patients	O
Undergoing	O
Neoadjuvant	O
Chemotherapy	O
Plus	O
Radical	O
Surgery	I:C0543467
.	O

Impact	O
of	O
Blood	O
Transfusions	I:C0005841
on	O
Survival	O
of	O
Locally	O
Advanced	O
Cervical	B:C4048328
Cancer	I:C4048328
Patients	O
Undergoing	O
Neoadjuvant	O
Chemotherapy	O
Plus	O
Radical	O
Surgery	I:C0543467
.	O

Impact	O
of	O
Blood	O
Transfusions	I:C0005841
on	O
Survival	O
of	O
Locally	O
Advanced	O
Cervical	O
Cancer	I:C4048328
Patients	O
Undergoing	O
Neoadjuvant	O
Chemotherapy	O
Plus	O
Radical	B:C0543467
Surgery	I:C0543467
.	O

Transfusions	B:C0005841
represent	O
one	O
of	O
the	O
main	O
progresses	O
of	O
modern	O
medicine	O
.	O

However	O
,	O
accumulating	O
evidence	O
supports	O
that	O
transfusions	B:C0005841
correlate	O
with	O
worse	O
survival	O
outcomes	O
in	O
patients	O
affected	O
by	O
solid	O
cancers	I:C0006826
.	O

However	O
,	O
accumulating	O
evidence	O
supports	O
that	O
transfusions	O
correlate	O
with	O
worse	O
survival	O
outcomes	O
in	O
patients	O
affected	O
by	O
solid	B:C0006826
cancers	I:C0006826
.	O

In	O
the	O
present	O
study	B:C0008972
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	O
transfusion	I:C0005841
in	O
locally	O
advanced	O
cervical	O
cancer	I:C4048328
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	B:C0005841
transfusion	I:C0005841
in	O
locally	O
advanced	O
cervical	O
cancer	I:C4048328
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	O
transfusion	I:C0005841
in	O
locally	B:C1517927
advanced	O
cervical	O
cancer	I:C4048328
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	O
transfusion	I:C0005841
in	O
locally	O
advanced	O
cervical	B:C4048328
cancer	I:C4048328
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	B:C1517927
advanced	O
cervical	O
cancer	I:C4048328
scheduled	O
to	O
undergo	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
were	O
retrospectively	O
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	O
on	O
survival	O
outcomes	O
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	O
advanced	O
cervical	B:C4048328
cancer	I:C4048328
scheduled	O
to	O
undergo	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
were	O
retrospectively	O
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	O
on	O
survival	O
outcomes	O
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	O
advanced	O
cervical	O
cancer	I:C4048328
scheduled	O
to	O
undergo	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	B:C0543467
surgery	I:C0543467
were	O
retrospectively	O
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	O
on	O
survival	O
outcomes	O
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	O
advanced	O
cervical	O
cancer	I:C4048328
scheduled	O
to	O
undergo	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
were	O
retrospectively	B:C0035363
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	O
on	O
survival	O
outcomes	O
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	O
advanced	O
cervical	O
cancer	I:C4048328
scheduled	O
to	O
undergo	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
were	O
retrospectively	O
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	B:C0005841
on	O
survival	O
outcomes	O
.	O

Five	O
-	O
year	O
survival	O
outcomes	O
were	O
evaluated	O
using	O
Kaplan	B:C2827659
-	I:C2827659
Meier	I:C2827659
and	O
Cox	O
models	I:C0010234
.	O

Five	O
-	O
year	O
survival	O
outcomes	O
were	O
evaluated	O
using	O
Kaplan	O
-	I:C2827659
Meier	I:C2827659
and	O
Cox	B:C0010234
models	I:C0010234
.	O

The	O
study	B:C0008972
included	O
275	O
patients	O
.	O

Overall	O
,	O
170	O
(	O
62	O
%	O
)	O
patients	O
had	O
blood	B:C0005841
transfusion	I:C0005841
.	O

Via	O
univariate	O
analysis	O
,	O
we	O
observed	O
that	O
transfusion	B:C0005841
correlated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
recurrence	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
2.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.09	O
-	O
4.40	O
;	O
P	O
=	O
0.02	O
)	O
.	O

Via	O
univariate	O
analysis	O
,	O
we	O
observed	O
that	O
transfusion	O
correlated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
recurrence	B:C1458156
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
2.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.09	O
-	O
4.40	O
;	O
P	O
=	O
0.02	O
)	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	B:C3272974
clinical	O
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	O
clinical	B:C4055223
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	O
clinical	O
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	B:C4050242
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	O
clinical	O
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	B:C4050242
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	O
clinical	O
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	B:C1518890
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	O
clinical	O
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	B:C0042232
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	O
clinical	O
response	I:C4055223
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	B:C0024204
node	I:C0024204
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

However	O
,	O
via	O
multivariate	O
analysis	O
,	O
only	O
vaginal	B:C0042232
(	O
HR	O
,	O
3.07	O
;	O
95	O
%	O
CI	O
,	O
1.20	O
-	O
7.85	O
;	O
P	O
=	O
0.01	O
)	O
and	O
lymph	O
node	I:C0024204
involvements	O
(	O
HR	O
,	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.00	O
-	O
6.06	O
;	O
P	O
=	O
0.05	O
)	O
correlate	O
with	O
worse	O
disease	O
-	O
free	O
survival	O
.	O

However	O
,	O
via	O
multivariate	O
analysis	O
,	O
only	O
vaginal	O
(	O
HR	O
,	O
3.07	O
;	O
95	O
%	O
CI	O
,	O
1.20	O
-	O
7.85	O
;	O
P	O
=	O
0.01	O
)	O
and	O
lymph	B:C0024204
node	I:C0024204
involvements	O
(	O
HR	O
,	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.00	O
-	O
6.06	O
;	O
P	O
=	O
0.05	O
)	O
correlate	O
with	O
worse	O
disease	O
-	O
free	O
survival	O
.	O

No	O
association	O
with	O
worse	O
outcomes	O
was	O
observed	O
for	O
patients	O
undergoing	O
blood	B:C0005841
transfusion	I:C0005841
(	O
HR	O
,	O
2.71	O
;	O
95	O
%	O
CI	O
,	O
0.91	O
-	O
8.03	O
;	O
P	O
=	O
0.07	O
)	O
.	O

Looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	B:C0024204
node	I:C0024204
status	O
(	O
P	O
=	O
0.01	O
)	O
and	O
vaginal	O
involvement	O
(	O
P	O
=	O
0.06	O
)	O
were	O
independently	O
associated	O
with	O
survival	O
.	O

Looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	O
node	I:C0024204
status	O
(	O
P	O
=	O
0.01	O
)	O
and	O
vaginal	B:C0042232
involvement	O
(	O
P	O
=	O
0.06	O
)	O
were	O
independently	O
associated	O
with	O
survival	O
.	O

The	O
role	O
of	O
blood	B:C0005841
transfusions	I:C0005841
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
LAAC	O
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
remains	O
unclear	O
;	O
further	O
prospective	O
studies	I:C0033522
are	O
warranted	O
.	O

The	O
role	O
of	O
blood	O
transfusions	I:C0005841
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	B:C1458156
in	O
LAAC	O
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
remains	O
unclear	O
;	O
further	O
prospective	O
studies	I:C0033522
are	O
warranted	O
.	O

The	O
role	O
of	O
blood	O
transfusions	I:C0005841
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
LAAC	B:C4048328
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
remains	O
unclear	O
;	O
further	O
prospective	O
studies	I:C0033522
are	O
warranted	O
.	O

The	O
role	O
of	O
blood	O
transfusions	I:C0005841
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
LAAC	O
patients	O
treated	B:C0332293
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
remains	O
unclear	O
;	O
further	O
prospective	O
studies	I:C0033522
are	O
warranted	O
.	O

The	O
role	O
of	O
blood	O
transfusions	I:C0005841
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
LAAC	O
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	B:C0543467
surgery	I:C0543467
remains	O
unclear	O
;	O
further	O
prospective	O
studies	I:C0033522
are	O
warranted	O
.	O

The	O
role	O
of	O
blood	O
transfusions	I:C0005841
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
LAAC	O
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	I:C0543467
remains	O
unclear	O
;	O
further	O
prospective	B:C0033522
studies	I:C0033522
are	O
warranted	O
.	O

